OTRAS SOCIEDADES

ESCCA_logo

EUROPEAN SOCIETY FOR CLINICAL CELL ANALYSIS (ESCCA): NEWSLETTER SEPTEMBER 2019.

ESCCA Board   13-09-2019   https://www.escca.eu    

 

Find attached the newsletter (September 2019) of the European Society for Clinical Cell Analysis (ESCCA).

 

 

SEI IPIC logo

IPOPI: Congreso IPIC 2019 (6-8 November, Madrid): 212 approved abstracts for poster presentation.

IPOPI (International Patient Organisation for Primary Immunodeficiencies)   07-09-2019   https://mailchi.mp/65f969be5da5/212-approved-abstracts?e=66f6ac33e7    

 

The IPIC2019 Organising and Scientific Committees have carefully reviewed all abstracts and approved 212 for poster presentation, a 21% increase from 2017. The 3 best posters have now been identified: 1st place: Dr. Del Pino Molina, L. (Spain) / 2nd place: Dr Karim, F. (netherlands) / 3rd place: Dr Raki Shirzad M. (Iran). The winners will be awarded a monetary prize and a dedicated session.

 

 

ESID_logo

NEWS@ESID - Summer Edition - August 2019

ESID (European Society for Immunodeficiencies).   02-09-2019   https://mailchi.mp/kenes.com/newsesid-spring-edition-august-2019?e=75f6add614    

 

Message from the President:

Dear colleagues and friends,
Time flies and September is approaching. If you took time off, I hope you enjoyed nice and refreshing holidays. With the Focused Meeting in Brussels literally around the corner, I welcome you all wholeheartedly, not only for the special focus on malignancy but also because you will get updates on recently described PID as well as some truly exciting unpublished work. Moreover, it is especially nice to welcome you to ESID in Brussels, the city where I was born, in my home country.

We are also working intensively with Aarn Huissoon and Peter Arkwright to prepare at least as nice a Biennial Meeting in Birmingham. Stay tuned and block out your agendas already for October 14-17, 2020.

As communicated in a previous letter, we have also worked on a draft strategic plan for ESID, starting to define and redefine our vision, mission and priorities as a society.

See full Newsletter in the link above.

 

 

ESCCA_logo

European Society for Clinical Cell Analysis (ESCCA): Newsletter July 2019.

ESCCA Board   07-07-2019   https://www.escca.eu    

 

Main topics:
-ESCCA 2019: Flowrescence in the Fjords.
-ESCCA 2020: Save the Date!
-Reminder: 6th International Summer School on Cytometry.
-4th ISCCA Congress.
-Announcement and Call for Papers.
-Flow Cytometry in Greece.
-Review of the 1st Summer School in Kos.

 

 

IPOPI_logo

IPOPI: e-News Summer 2019

IPOPI   25-06-2019   https://mailchi.mp/66767ba247cb/e-news-summer-2019?e=213bc260c3    

 

“Putting primary immunodeficiency patients at the centre of their care”, the 2019 edition of World Primary Immunodeficiencies Week intended to place patient-centered care at the heart of the campaign. And what a successful outcome! First of all, let’s talk about how pleased we are to have had so many of our NMOs committed in this year’s issue. Thanks to the great support of its corporate partners, IPOPI was able to support 31 NMOs in their awareness and advocacy efforts. PIDs stood high on the agenda in all continents, with so many countries involved in an array of campaigns and awareness raising programmes including family meetings, exhibitions, stakeholders’ roundtables, media campaign, races and challenges, trainings…

See full e-News Summer 2019 in the link above.

 

 

IPOPI_logo

IPIC2019: Abstract submission deadline extended (June 20, 2019).)

IPOPI (International Patient Organisation for Primary Immunodeficiencies))   01-06-2019   https://mailchi.mp/69db1129dc54/ipic2019-registration-open-2955409?e=66f6ac33e7    

 

The IPIC2019 Scientific Committee has decided to extend the deadline for abstract submission to June 30 to allow the many of you eager to submit but in need of some extra time to do so!

Don't miss this last chance to submit your original contributions to the field of clinical care of primary immunodeficiencies (PIDs).

The winners will also have the opportunity to give an oral presentation of their posters in a dedicated congress session.

 

 

ESID_logo2

Professor Jaak Vossen Obituary

ESID (European Society for Immunodeficiencies).   18-05-2019   https://mailchi.mp/986b4a3037b1/newsesid-spring-edition-april-2654313?e=75f6add614    

 

Jaak Vossen passed away on April 30th 2019 at the age of 81 year. He studied medicine in Leuven (Belgium) and after his residency he worked as paediatrician in the Academic Hospital in Leiden from 1968, and from 1979 to 2002 as professor - holding a chair in paediatric immunology.

Together with the paediatricians J. de Koning and L.J. Dooren and transplantation pioneers Dick van Bekkum and Jon van Rood, Jaak was involved in the first successful stem cell transplantations (SCT) in children in Europe. The first SCT procedures were performed in children with severe immunodeficiencies and aplastic anaemia, and from the eighties also in children with leukaemia. Besides having a broad general knowledge of paediatric medicine Jaak was an international expert in transplantation-immunology. He was an intermediate between clinical medicine and more fundamental laboratory immunology.

 

 

ESID_logo2

Lymphocyte adhesion deficiency type 1 protocol.

ESID (European Society for Immunodeficiencies).   15-05-2019   https://mailchi.mp/kenes.com/fellowship-call-for-applications-rare-diseases-of-the-immune-system-from-pathophysiology-to-new-therapies-2654309?e=75f6add614    

 

Dear ESID Members,

We would like to share with you the following details on the Lymphocyte adhesion deficiency type 1 active approved protocol at NIH.

LAD1: An open-label, proof-of-concept study to evaluate efficacy, safety and tolerability of ustekinumab to control gingival inflammation in LAD1 is open at the US National Institute of Health. Participants get 5 doses of ustekinumab over 1 year. They will be followed for adverse events as well as the effect of the drug on inflammatory lesions and biomarkers. There is no charge for this study, but only domestic US travel is covered.

Relevant publication: PMID: 28328326.
Clinicaltrials.gov identifier number: NCT03366142.
Investigators: Beatriz E. Marciano, Steven Holland.
Contact: Dawn Shaw, dawn.shaw2@nih.gov.

 

 

ESID_logo2

NEWS@ESID - Spring Edition - April 2019

ESID (European Society for Immunodeficiencies).   23-04-2019   https://mailchi.mp/kenes.com/newsesid-spring-edition-april-2654301?e=75f6add614    

 

Message from the President:

Dear colleagues and friends,
It has been a very busy spring. With the board, we have had a fruitful strategic meeting in February of which I have previously communicated an important outcome. Other goals for the future were set out. More particularly, we wish to move closer to you, ESID members, and to engage more actively with you in ongoing ESID research, educational activities, etc.
Don’t forget about World PI Week: actions, however small, to enhance awareness are a crucial first step in the diagnosis and treatment of PID patients. Too many patients are still undiagnosed. This year’s theme is particularly important as indeed PID patients need patient centred care.
Finally, I personally hope to be able to welcome you and spend time with you at ESID 2019 focused meeting in my home country. In the meantime, do not hesitate to reach out for any suggestions, questions you may have.

Please, find the NEWSLETTER in the link above.

 

 

ESID_logo2

ESID Fellowships - Application Deadline 25 April 2019.

ESID (European Society for Immunodeficiencies).   06-04-2019   https://mailchi.mp/kenes.com/fellowship-call-for-applications-rare-diseases-of-the-immune-system-from-pathophysiology-to-new-therapies-2654293?e=75f6add614    

 

Dear ESID Members,

We would like to remind you about the upcoming deadline to apply for the ESID short- and medium-term fellowships.

Short-term fellowship:
Scholarships of EUR 1,500 plus up to EUR 500 as travel support are available for current ESID Junior members. Travel costs can be claimed after the completion of the fellowship from the secretariat upon the submission and approval of the final report.
Each short-term program should last between 1-2 months.

Medium-term fellowship:
Medium-term fellowships will be awarded to current ESID Junior members who are physicians or scientists in specialist training, interested in pursuing a research project in the field of primary immunodeficiencies.

See link above for full details.